Before-surgery chemoradiation plus PD-1 for locally advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial studies giving long-course radiation and chemotherapy before surgery, plus an immunotherapy medicine (PD-1) to help the tumor shrink more. It’s for people with stage II or III rectal cancer that has not spread to distant organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 75 years old
- Have a good functional status (ECOG 0–2—able to do most daily activities)
- Have biopsy-proven rectal adenocarcinoma located within 10 cm of the anus, and it must be stage II or III by MRI without distant spread
- Have not had any cancer treatment before for this illness (no prior radiation, chemo, immunotherapy, etc.)
- Have no immune system or autoimmune diseases (and no HIV infection)
- Have blood tests and organ function strong enough for treatment (examples include enough white cells, hemoglobin, platelets, and acceptable kidney and liver numbers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This study tests a combination of chemotherapy, radiation, and an immunotherapy drug (called anti-PD-1) before surgery for rectal cancer that has not spread. The goal is to see if this approach can shrink or eliminate the tumor, potentially improving outcomes.
This study tests two different radiation regimens (long-course vs. short-course) combined with chemotherapy (CAPOX), an immunotherapy drug (PD-1 antibody), and a COX-2 inhibitor for people with MSS locally advanced rectal cancer. The goal is to see which approach works better in shrinking the tumor before surgery.
This trial tests whether a combination of chemotherapy, radiation, and an immunotherapy drug (tislelizumab) before surgery can improve outcomes for people with locally advanced rectal cancer that has specific protein/gene markers (pMMR or MSS). It’s designed for those who have not yet had any treatment for their cancer.
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
This trial tests a treatment plan for locally advanced rectal cancer that combines chemotherapy and radiation with an immunotherapy drug (PD-1 inhibitor) before surgery. The goal is to shrink the tumor and improve the chance of successful surgery and long-term control.
Hear when a new Locally Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.